Compound timicosin oral liquid and preparation method thereof

A technology of micosin oral liquid and tilmicosin, which is applied in the field of compound tilmicosin oral liquid and its preparation, can solve the problems of poor bacteriostatic, bactericidal and antiviral treatment, not a single active ingredient, etc. Immunity, high drug concentration, strong antibacterial effect

Inactive Publication Date: 2011-04-06
NORTHWEST A & F UNIV
View PDF4 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But current tilmicosin medicine has more than single active ingredient, and its antibacterial, bactericidal and antiviral treatments are poor.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound timicosin oral liquid and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Embodiment 1 Preparation of compound tilmicosin oral liquid

[0032] Prepare the recipe as follows:

[0033] Tilmicosin 3.5000g

[0034] Astragalus polysaccharide 0.6000g

[0035] Chlorogenic acid 0.2000g

[0036] Radix Radix Polysaccharide 0.2000g

[0037] Ethanol 0.4000g

[0038] Disodium EDTA 0.0200g

[0039] Citric acid 1.000g

[0040] Propyl gallate 0.0004g

[0041] Sodium benzoate 0.0020g

[0042] Distilled water 4.0776g

[0043] Specific steps:

[0044] 1) Weighing tilmicosin, astragalus polysaccharide, chlorogenic acid, isatidis polysaccharide, chlorogenic acid cosolvent, tilmicosin solvent, tilmicosin cosolvent, antioxidant, preservative for subsequent use;

[0045] 2) Add 45% distilled water to the tilmicosin solvent to dissolve it;

[0046] 3) Add 20% of the total amount of tilmicosin to the tilmicosin co-solvent, then add the solution prepared in step 2), stir continuously, and after mixing evenly, add 30% and 50% tilmicosin in turn ;

[0047] 4...

Embodiment 2

[0051] Example 2 Preparation of compound tilmicosin oral liquid

[0052] Tilmicosin 2.0000g

[0053] Astragalus polysaccharide 2.0000g

[0054] Chlorogenic acid 0.2000g

[0055] Radix Radix Polysaccharide 0.3000g

[0056] Ethanol 0.4000g

[0057] Disodium EDTA 0.0200g

[0058] Citric acid 0.6000g

[0059] Sodium thiosulfate 0.0004g

[0060] Sodium Benzoate 0.0100g

[0061] Distilled water 4.4696g

Embodiment 3

[0062] Example 3 Preparation of compound tilmicosin oral liquid

[0063] Tilmicosin 0.5000g

[0064] Astragalus polysaccharide 0.3000g

[0065] Chlorogenic acid 2.0000g

[0066] Radix Radix Polysaccharide 0.2000g

[0067] Ethanol 4.0000g

[0068] Disodium EDTA 0.0050g

[0069] Citric acid 0.1000g

[0070] Propyl gallate 0.0010g

[0071] Benzoic acid 0.0020g

[0072] Distilled water 2.8920g

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses compound timicosin oral liquid, which comprises the following raw materials in percentage by weight: 5 to 40 percent of timicosin, 2 to 20 percent of astragalus polysaccharide, 2 to 20 percent of chlorogenic acid, 2 to 15 percent of indigowoad root polysaccharide, 4 to 40 percent of chlorogenic acid cosolvent, 0.5 to 2 percent of chelating agent, 0 to 25 percent of timicosin cosolvent, 0.9 to 10 percent of timicosin solvent, 0.004 to 0.01 percent of antioxidant, 0.02 to 0.1 percent of preservative, and 16 to 85 percent of distilled water. The timicosin is matched with the chlorogenic acid, the astragalus polysaccharide and the extract of indigowoad root to perform the complementary effects of different action mechanisms, so that the stronger effects of resisting bacteria and viruses and improving immunity are realized.

Description

technical field [0001] The invention belongs to the technical field of veterinary medicine, and relates to a compound tilmicosin oral liquid which is used for treating diseases caused by respiratory bacteria and mycoplasma infection in livestock and poultry and has antiviral and immunity-improving effects and a preparation method thereof. technical background [0002] Tilmicosin is a macrolide antibiotic specially used for livestock and poultry, with a broad antibacterial spectrum and strong antibacterial activity. It has inhibitory effect on Gram-positive bacteria and some Gram-negative bacteria, mycoplasma, spirochetes, etc. It is mainly used to treat infection diseases caused by sensitive bacteria in cattle, goats, sheep, dairy cows, pigs, chickens and other animals. However, the current tilmicosin drugs have more than a single active ingredient, and their antibacterial, bactericidal and antiviral treatments are poor. Contents of the invention [0003] In view of the d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/715A61K31/706A61K31/216A61K9/08A61P31/04A61P11/00A61P31/16
Inventor 欧阳五庆王璟李雅
Owner NORTHWEST A & F UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap